SCHEMBL447088

SCHEMBL447088

c1ccc(C2CC(N3CCCC3)C2)cc1

nearest known ligand 0.72

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.72
CYP2D6 P10635 3/20 0.62
CYP2C19 P33261 1/20 0.62
SLC18A3 Q16572 5/20 0.56
GRIN2B Q13224 3/20 0.50
SIGMAR1 Q99720 4/20 0.49
L3MBTL3 Q96JM7 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
MBTD1 Q05BQ5 1/20 0.48
KMT2A Q03164 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HPGD P15428 1/20 0.47
HRH3 Q9Y5N1 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
TSHR P16473 1/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1003630 0.80 LTA4H (0.58) LTA4HCYP2D6CYP2C19SLC18A3SIGMAR1
SCHEMBL28702035 0.80 CYP2D6 (0.93) CYP2D6CYP2C19SLC18A3GRIN2BL3MBTL3
SCHEMBL13660519 0.80 SLC18A3 (0.57) LTA4HCYP2D6CYP2C19SLC18A3SIGMAR1
SCHEMBL447356 0.79 SLC18A3 (0.50) LTA4HCYP2D6CYP2C19SLC18A3SIGMAR1
SCHEMBL15184744 0.78 CYP2D6 (0.83) CYP2D6CYP2C19SLC18A3GRIN2BL3MBTL3
SCHEMBL13498019 0.77 CYP2D6 (1.00) CYP2D6CYP2C19SLC18A3GRIN2BSIGMAR1
SCHEMBL5007409 0.77 AKR1C3 (0.51) LTA4HCYP2D6CYP2C19CYP1A2CYP2C9
SCHEMBL444560 0.77 AKR1C3 (0.56) LTA4HCYP2D6CYP2C19SLC18A3GRIN2B
SCHEMBL3630710 0.76 LTA4H (0.47) LTA4HCYP2D6CYP2C19SLC18A3GRIN2B
SCHEMBL5000672 0.74 LTA4H (0.53) LTA4HCYP2D6CYP2C19SLC18A3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2012-03-15 US disclosed
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions PFIZER INC. 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 LTA4H 2266/4885CYP2D6 2/4885CYP2C19 13/4885
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions XDH, CYP2D6, F12 LTA4H 2266/4885CYP2D6 2/4885CYP2C19 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.